Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial (IMPACT2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02781220 |
Recruitment Status : Unknown
Verified January 2020 by Norman Foster, University of Utah.
Recruitment status was: Active, not recruiting
First Posted : May 24, 2016
Last Update Posted : January 28, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Mild Cognitive Impairment Dementia Alzheimer's Disease |
The primary purpose of this prospective, observational study is to examine the benefit of amyloid positron emission tomography and computed tomography (PET/CT) scan in clinical practice for participants at our site that are enrolled in the IDEAS (NCT02420756) trial. To accomplish this, when a clinician has ordered an amyloid PET scan, the investigators will assess the impact of [18F]Flutemetamol PET/CT scans on 1) physician diagnosis and management as it relates to care practices and drug management, and 2) patient reported outcomes in patients evaluated in the Cognitive Disorders Clinic at the University of Utah and meeting Appropriate Use Criteria (AUC) for clinical amyloid PET/CT scans. A secondary purpose is to compare the semi-quantitative assessment of amyloid plaque burden using vendor supplied software and standard visual assessment of amyloid positivity.
The primary hypothesis is that, in diagnostically uncertain cases, knowledge of amyloid status as determined by amyloid PET/CT scans may alter patient diagnosis and management and lead to significant changes in patient and family reported outcomes. A secondary hypothesis is that vendor supplied semi-quantitative assessment of amyloid plaque positivity will be superior to standard visual criteria assessments.
Objectives
AIM 1: to assess the change in diagnosis and management, related to care practices and drug management of adult patients being evaluated for cognitive deficits and meeting Appropriate Use Criteria (AUC)
AIM 2: to assess the change of amyloid PET/ CT scans on patient-reported outcomes involving care partner confidence and satisfaction
AIM 3: to assess confidence increase through use of vendor supplied semi-quantitative software
AIM 4: to assess adherence to identified patient management related to care practices and drug management
Study Type : | Observational |
Actual Enrollment : | 69 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial |
Study Start Date : | July 2016 |
Actual Primary Completion Date : | July 2018 |
Estimated Study Completion Date : | July 2021 |

Group/Cohort |
---|
Qualifying participants
All consented IDEAS trial participants will have additional data collected: visual and semi-quantitative software aided amyloid PET scan interpretation, care partner questionnaires and documented provider diagnosis, diagnostic confidence, and management plan following the IMPACT design
|
- Percentage of change in care practices after amyloid PET scan [ Time Frame: Visit 1, 30 days prior to scan and Visit 4, 90 days after scan ]% of 13 care practices that differ before and after the amyloid PET scan
- Percentage of change in drug management options after amyloid PET [ Time Frame: Visit 1, 30 days prior to scan and Visit 4, 90 days after scan ]% of drug management options that differ before and after the amyloid PET scan
- Change in % likelihood of Alzheimer's disease (AD) diagnosis after amyloid PET scan [ Time Frame: Visit 1, 30 days prior to scan and Visit 4, 90 days after scan ]Difference in % of AD likelihood identified before and after the amyloid PET scan
- Percentage of change in leading diagnosis after amyloid PET [ Time Frame: Visit 1, 30 days prior to scan and Visit 4, 90 days after scan ]% of leading diagnosis that differ before and after amyloid PET scan
- Change in physician confidence in leading diagnosis [ Time Frame: Visit 1, 30 days prior to scan and Visit 4, 90 days after scan ]Difference in 5-point scale of physician confidence in leading diagnosis before and after amyloid PET scan
- Change in care partner's confidence in diagnosis after amyloid PET [ Time Frame: Visit 1, 30 days prior to scan, Visit 4, 90 days after scan, Visit 5, 180 days after scan and Visit 6, 270 days after scan ]Difference in 5-point scale of care partner confidence in diagnosis before and after amyloid PET scan
- Change in care partner satisfaction with evaluation after amyloid PET [ Time Frame: Visit 1, 30 days prior to scan and Visit 4, 90 days after scan ]Difference in 5-point scale of care partner satisfaction before team care and after amyloid PET scan
- Change in care partner assessment of the quality of evaluation after amyloid PET [ Time Frame: Visit 1, 30 days prior to scan and Visit 4, 90 days after scan ]Difference in 5-point scale of care partner quality before team care and after amyloid PET scan
- Proportion of care partners finding amyloid PET scan worthwhile [ Time Frame: Visit 4, 90 days after scan ]Proportion of care partners indicating they would agree to do an amyloid PET again on a yes/no/don't know scale
- Proportion exhibiting increased behavior disturbance during amyloid scan visit [ Time Frame: Visit 1, Visit 2, Visit 3, and Visit 4 90 days post scan ]% of patients showing a difference in the 44-point Catastrophic Reaction Scale between the median value in all non-scan visits and the value in the amyloid PET scan visit
- Percentage of change exhibiting increased behavior disturbance when the diagnosis is given [ Time Frame: Visit 1, Visit 3, 60 days ]% of patients showing a difference in the 44-point Catastrophic Reaction Scale between Visit 1 and Visit 3 when learning the result of the scan
- Care partner's sustained confidence in diagnosis received after amyloid PET scan [ Time Frame: Visit 4, Visit 5, and Visit 6, 270 days post scan ]Care partner confidence in diagnosis received after amyloid PET scan on a 5-point scale
- Care partner's sustained confidence in ability to adhere to management plan received after amyloid PET scan [ Time Frame: Visit 4, Visit 5, and Visit 6, 270 days post scan ]Care partner confidence in ability to follow management plan outlined by physician after amyloid PET scan on a 5-point scale
- Percentage of recommended care practices adhered to after amyloid PET scan [ Time Frame: Visit 4, Visit 5, and Visit 6, 270 days post scan ]% of care practices recommended after amyloid PET scan reported by care partner
- Percentage of recommended drug management adhered to after amyloid PET scan [ Time Frame: Visit 4, Visit 5, and Visit 6, 270 days post scan ]% of drug management options recommended after amyloid PET scan reported by care partner
- Change in the interpretation of amyloid PET scans with semi-quantitative image analysis [ Time Frame: within 30 days post amyloid PET scan ]Difference in a 5-point measure of amyloid scan positivity between a qualitative and semi-quantitative image analysis

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- 65 and older;
- Medicare beneficiary;
- Diagnosis of mild cognitive impairment (MCI) or dementia, according to Diagnostic and Statistical Manual - IV (DSM-IV) and/or National Institutes of Aging-Alzheimer's Association criteria, verified by a dementia specialist within 24 months (American Psychiatric Association. 2000; McKhann et al. 2011; Albert et al. 2011);
- Meets AUC:
- Cognitive complaint verified by objectively confirmed cognitive impairment;
- The etiologic cause of cognitive impairment is uncertain after a comprehensive evaluation by a dementia specialist, including general medical and neurological examination, mental status testing including standard measures of cognitive impairment, laboratory testing, and structural neuroimaging as below;
- Alzheimer's disease is a diagnostic consideration;
- Knowledge of amyloid PET status is expected to alter diagnosis and management.
- Head MRI and/or CT within 24 months prior to enrollment;
- Clinical laboratory assessment within the 12 months prior to enrollment: complete blood count (CBC), standard blood chemistry profile, thyroid stimulating hormone (TSH); vitamin B12;
- Able to tolerate amyloid PET required by protocol, to be performed at a participating PET facility;
- English or Spanish speaking (for the purposes of informed consent);
- Willing and able to provide consent. Consent may be by proxy.
Exclusion Criteria:
- Normal cognition or subjective complaints that are not verified by cognitive testing.
- Knowledge of amyloid status, in the opinion of the referring dementia expert, may cause significant psychological harm or otherwise negatively impact the patient or family.
- Scan is being ordered solely based on a family history of dementia, presence of apolipoprotein E, or in lieu of genotyping for suspected autosomal mutation carriers.
- Scan being ordered for nonmedical purposes (e.g., legal, insurance coverage, or employment screening).
- Cancer requiring active therapy (excluding non-melanoma skin cancer);
- Hip/pelvic fracture within the 12 months prior to enrollment;
- Body weight exceeds PET scanner weight limit;
- Life expectancy less than 24 months based on medical co-morbidities;
- Residence in a skilled nursing facility.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02781220
United States, Utah | |
Center for Alzheimer's Care, Imaging & Research | |
Salt Lake City, Utah, United States, 84108-1225 |
Principal Investigator: | Norman L. Foster, M.D. | Director: Center for Alzheimer's Care, Imaging & Research; Chief: Division of Cognitive Neurology; Senior Investigator: The Brain Institute; Professor: Dept. of Neurology University of Utah School of Medicine |
Publications:
Responsible Party: | Norman Foster, Director: Center for Alzheimer's Care, Imaging & Research; Chief: Division of Cognitive Neurology; Senior Investigator: The Brain Institute; Professor: Dept. of Neurology University of Utah School of Medicine, University of Utah |
ClinicalTrials.gov Identifier: | NCT02781220 |
Other Study ID Numbers: |
IMPACT-2 |
First Posted: | May 24, 2016 Key Record Dates |
Last Update Posted: | January 28, 2020 |
Last Verified: | January 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | only de-identified data will be shared |
MCI Dementia amyloid PET physician diagnosis Alzheimer's disease |
AD PET imaging Appropriate Use Criteria patient-reported outcomes patient adherence |
Alzheimer Disease Dementia Cognitive Dysfunction Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Cognition Disorders |